1 1

FDA ANDA 214348, BUPIVACAINE LIPOSOME, HENGRUI PHARMA, 07/01/2024

FDA ANDA 214348, BUPIVACAINE LIPOSOME, HENGRUI PHARMA, 07/01/2024

$89.00 USD
$89.00 USD
Sale Sold out

Contents: Summary Basis of Approval (or similar) for ANDA 214348 [Bupivacaine Liposome Injectable Suspension, 1.3% [133 mg/10 mL (13.3 mg/mL)] and 1.3% [266 mg/20 mL (13.3 mg/mL)] Single Dose Vials]

ANDA: 214348
Company: HENGRUI PHARMA
Drug Name: BUPIVACAINE LIPOSOME
Active Ingredients: BUPIVACAINE
Strength: 266MG/20ML (13.3MG/ML)
Dosage Form/Route: INJECTABLE, LIPOSOMAL;INJECTION
Action Date: 07/01/2024
Marketing Status: Prescription
Submission Classification: ORIG-1

6 Pages
View full details
FOIA Pro

This drug has a lot more FDA history than one product page can show

FOIA Pro gives you full-text search across 70,000+ FDA FOIA records, from 2020 through today, plus a monthly monitor tracking new requests as they close.
  • Full-text search across every FDA FOIA log since 2020
  • Warning letters, approval records, and correspondence in one place
  • Monthly FDA FOIA Monitor newsletter, included
  • Cancel anytime, monthly or annual billing
Get FOIA Pro
Live search · FOIA database
Searching related FDA records…
ClosedTypeSubjectOutcome